losartan-potassium has been researched along with Monkey-Diseases* in 4 studies
4 other study(ies) available for losartan-potassium and Monkey-Diseases
Article | Year |
---|---|
Plasmodium coatneyi in rhesus macaques replicates the multisystemic dysfunction of severe malaria in humans.
Severe malaria, a leading cause of mortality among children and nonimmune adults, is a multisystemic disorder characterized by complex clinical syndromes that are mechanistically poorly understood. The interplay of various parasite and host factors is critical in the pathophysiology of severe malaria. However, knowledge regarding the pathophysiological mechanisms and pathways leading to the multisystemic disorders of severe malaria in humans is limited. Here, we systematically investigate infections with Plasmodium coatneyi, a simian malaria parasite that closely mimics the biological characteristics of P. falciparum, and develop baseline data and protocols for studying erythrocyte turnover and severe malaria in greater depth. We show that rhesus macaques (Macaca mulatta) experimentally infected with P. coatneyi develop anemia, coagulopathy, and renal and metabolic dysfunction. The clinical course of acute infections required suppressive antimalaria chemotherapy, fluid support, and whole-blood transfusion, mimicking the standard of care for the management of severe malaria cases in humans. Subsequent infections in the same animals progressed with a mild illness in comparison, suggesting that immunity played a role in reducing the severity of the disease. Our results demonstrate that P. coatneyi infection in rhesus macaques can serve as a highly relevant model to investigate the physiological pathways and molecular mechanisms of malaria pathogenesis in naïve and immune individuals. Together with high-throughput postgenomic technologies, such investigations hold promise for the identification of new clinical interventions and adjunctive therapies. Topics: Anemia; Animals; Blood Coagulation; Bone Marrow Diseases; Disease Models, Animal; Erythropoiesis; Erythropoietin; Macaca mulatta; Malaria; Male; Monkey Diseases; Plasmodium; Random Allocation; Time Factors | 2013 |
Chronic anemia and effects of iron supplementation in a research colony of adult Rhesus macaques (Macaca mulatta).
A cohort of rhesus macaques used in neuroscience research was found at routine examinations to have chronic anemia (spun Hct less than 30%). Four anemic (Hct, 24.8% ± 3.4%) and 10 control (39.6% ± 2.9%) macaques were assessed to characterize the anemia and determine probable cause(s); some animals in both groups had cephalic implants. Diagnostic tests included CBC, bone marrow evaluations, iron panels, and serum erythropoietin and hepcidin concentrations. Serum iron and ferritin were 15.8 ± 11.1 μg/dL and 103.8 ± 53.1 ng/mL, respectively, for the anemic group compared with 109.8 ± 23.8 μL/dL and 88.5 ± 41.9 ng/mL, respectively, for the control group. Erythropoietin levels were 16.2 to over 100 mU/mL for the anemic macaques compared with 0 to 1.3 mU/mL for the control group. Hepcidin results were similar in both groups. Because the findings of low iron, high erythropoietin, and normal hepcidin in the anemic macaques supported iron-deficiency anemia or anemia of chronic disease combined with iron-deficiency anemia, a regimen of 4 doses of iron dextran was provided. In treated macaques, Hct rose to 36.3% ± 6.8%, serum iron levels increased to 94.0 ± 41.9 μg/dL, and erythropoietin levels fell to 0.15 to 0.55 mU/mL. Maintenance of normal Hct was variable between macaques and reflected individual ongoing clinical events. Topics: Age Factors; Anemia, Iron-Deficiency; Animals; Animals, Laboratory; Antimicrobial Cationic Peptides; Biomarkers; Blood Cell Count; Bone Marrow Examination; Chronic Disease; Dietary Supplements; Erythropoietin; Female; Ferritins; Hematinics; Hematocrit; Hepcidins; Iron; Iron Compounds; Macaca mulatta; Male; Monkey Diseases; Time Factors; Treatment Outcome | 2012 |
Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model.
The renoprotective effect of erythropoietin (Epo) against ischaemia-reperfusion injury (IR/I) was evaluated in a non-human primate model.. Crab-eating macaques were divided into two groups: Control (n = 10), treated with saline, and EPO (n = 10), treated with Epo. Epo was injected intravenously at a dose of 12,000 units, 5 min before clamping the renal pedicle and 5 min before declamping. Renal IR/I was created by clamping the left renal artery for 90 min following right nephrectomy. Haemoglobin (Hb), haematocrit (Ht), creatinine (Cr), blood urea nitrogen (BUN), cystatin C and interleukin-6 (IL-6) were measured before (Pre) and after (Day 0) the operation, and on post-operative days: Day 1, Day 3, Day 5 and Day 7. Apoptotic cells were counted on Day 1.. There were no differences in Hb and Ht between the two groups. Cr, BUN, cystatin C and IL-6 levels in the EPO group were lower than those in the Control group at most of the observation points. The number of apoptotic cells in the Control was significantly higher than that of and EPO group.. Epo significantly ameliorates renal IR/I in this non-human primate model. Our findings justify the clinical application of Epo, not only for acute renal failure, but also in transplantation. Topics: Animals; Apoptosis; Creatinine; Disease Models, Animal; Erythropoietin; Humans; Kidney Function Tests; Macaca fascicularis; Male; Monkey Diseases; Reperfusion Injury | 2011 |
EPO and HO-1 in cardiovascular and renal protection: just a common signaling pathway or a mechanistic link?
Topics: Animals; Disease Models, Animal; Erythropoietin; Humans; Male; Monkey Diseases; Reperfusion Injury | 2011 |